Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.34 USD
Change Today -0.032 / -0.95%
Volume 12.0K
CLRB On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/2/14 - $9.20
52 Week Low
10/20/14 - $1.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Compensation as of Fiscal Year 2013.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma

Cellectar Biosciences, Inc. announced the initiation of patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma, an indication for which I-131-CLR1404 previously received orphan drug designation from the U.S. Food and Drug Administration. Multiple myeloma is an incurable malignancy for which novel therapies are needed. The radiosensitivity of multiple myeloma is well documented. I-131-CLR1404 is designed to allow for targeted delivery of ionizing radiation to malignant cells, allowing for an intracellular radiation mechanism of cancer cell killing regardless of anatomic distribution. This is a multi-center, open-label, sequential group, dose escalation, Phase I proof-of-concept study evaluating the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone, in multiple myeloma patients who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. The secondary objectives of the study are to identify a recommended Phase II dose and assess therapeutic activity of I-131-CLR1404 in relapsed or refractory multiple myeloma. Therapeutic activity will be assessed by overall response rate, time to progression and duration of response. Patients will be enrolled into cohorts that receive escalating single doses of I-131-CLR1404 combined with a set dose of dexamethasone. The first cohort of subjects will receive a 12.5 mCi/m2 dose of I-131-CLR1404. A minimum of three subjects will be enrolled at each dose level. Dose escalation and level expansion will be guided by safety and will be performed after all subjects in a cohort have been followed for 12 weeks.

Cellectar Biosciences, Inc. Reports Earnings Results for the Year Ended December 31, 2014

Cellectar Biosciences, Inc. reported earnings results for the year ended December 31, 2014. The company reported a net loss attributable to common stockholders for the year ended December 31, 2014 of approximately $8.1 million or $1.77 per share compared to a net loss attributable to common stockholders of approximately $10.8 million or $3.86 per share for the year ended December 31, 2013.

Cellectar Biosciences, Inc. Auditor Raises 'Going Concern' Doubt

Cellectar Biosciences, Inc. filed its 10-K on Mar 24, 2015 for the period ending Dec 31, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $3.34 USD -0.032

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at